Cargando…
Imagining a Better Outcome for Chronic Antibody-Mediated Rejection—Will Blocking Interleukin-6 Signaling Help?
Autores principales: | Muthukumar, Thangamani, Crew, R. John |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039899/ https://www.ncbi.nlm.nih.gov/pubmed/35497807 http://dx.doi.org/10.1016/j.ekir.2022.02.026 |
Ejemplares similares
-
How Do We Interpret the Presence of Donor-Specific Antibodies When There Is No Rejection?
por: Crew, R. John, et al.
Publicado: (2019) -
Rituximab use in late antibody-mediated rejection
por: Bansal, S. B.
Publicado: (2016) -
Post-Transplant Hypotension in Kidney Recipients—Vasopressin to the Rescue?
por: Bajpai, Divya, et al.
Publicado: (2022) -
Can COVID-19 innovations and systems help low- and middle-income countries to re-imagine healthcare delivery?
por: Saha, Senjuti, et al.
Publicado: (2021) -
Discovering chronic pain treatments: better animal models might help us get there
por: Taylor, Norman E., et al.
Publicado: (2023)